Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823906 | 0.84 | TSHR (0.53) | LMNARAB9ATSHRTDP1SMN1; SMN2 | |
| SCHEMBL7076638 | 0.76 | CYP19A1 (0.48) | CYP19A1LMNATSHRVCAM1POLB | |
| SCHEMBL14337755 | 0.74 | F2RL3 (0.42) | CYP19A1LMNAIDO1TSHRVCAM1 | |
| SCHEMBL11273785 | 0.74 | CYP19A1 (0.50) | CYP19A1LMNAIDO1TSHRVCAM1 | |
| SCHEMBL10015973 | 0.73 | MAPT (0.44) | CYP19A1RAB9APOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL29080392 | 0.73 | CYP19A1 (0.45) | CYP19A1LMNARAB9ATSHRVCAM1 | |
| SCHEMBL7005138 | 0.73 | CYP19A1 (0.45) | CYP19A1LMNAERN1IDO1TSHR | |
| SCHEMBL26343368 | 0.72 | SMN1; SMN2 (0.42) | CYP19A1RAB9ACYP3A4SMN1; SMN2HTT | |
| SCHEMBL3055585 | 0.72 | TDP1 (0.44) | LMNARAB9AIDO1TSHRPOLB | |
| SCHEMBL10352515 | 0.72 | ALDH1A1 (0.45) | CYP19A1LMNARAB9AIDO1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425518-A1 | N-MACROCYCLIC AMIDE COMPOUNDS, PREPARATION METHODS THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20200297724-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL INC. | 2020-09-24 | — | — | US | disclosed |
| US-10456397-B2 | Covalent inhibitors of CDK-7 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190151316-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL LLC | 2019-05-23 | — | — | US | disclosed |
| US-10195200-B2 | Covalent inhibitors of CDK-7 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180008604-A1 | COVALENT INHIBITORS OF CDK-7 | NEWAVE PHARMACEUTICAL LLC | 2018-01-11 | — | — | US | disclosed |
| WO-2008060248-A1 | INDOLE SUSTITUTED PYRIMIDINES AND USE THEREOF IN THE TREATMENT OF CANCER | S*BIO PTE LTD. (SG) | 2008-05-22 | — | — | WO | disclosed |
| EP-0635533-B1 | Polyimide-based liquid crystal aligning agent | SAGAMI CHEM RES (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0452725-B1 | Fluorine containing diaminobenzene derivatives and its use | SAGAMI CHEM RES (JP) | 1995-11-08 | — | — | EP | disclosed |
| EP-0635533-A1 | Polyimide-based liquid crystal aligning agent | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5153304-A | Polyimides; liquid crystal tilting agent; water-repelling | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-10-06 | — | — | US | disclosed |
| US-5144078-A | Polyimide intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0452725-A2 | Fluorine containing diaminobenzene derivatives and its use | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456397-B2 | Covalent inhibitors of CDK-7 | CDK7, CDKL1, CDK1 | CYP19A1 589/4885LMNA 2960/4885RAB9A 1484/4885 |
| US-20240425518-A1 | N-MACROCYCLIC AMIDE COMPOUNDS, PREPARATION METHODS THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS | ZYX, MLX, LPXN | CYP19A1 321/4885LMNA 138/4885RAB9A 3749/4885 |
| US-20190151316-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | CYP19A1 589/4885LMNA 2960/4885RAB9A 1484/4885 |
| US-20200297724-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | CYP19A1 589/4885LMNA 2960/4885RAB9A 1484/4885 |
| US-20180008604-A1 | COVALENT INHIBITORS OF CDK-7 | CDK7, CDKL1, CDK1 | CYP19A1 589/4885LMNA 2960/4885RAB9A 1484/4885 |
| US-10195200-B2 | Covalent inhibitors of CDK-7 | CDK7, CDKL1, CDK1 | CYP19A1 589/4885LMNA 2960/4885RAB9A 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.